Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project

Drug Testing and Analysis

Volumn 9, Issue 2, 2017, Pages 188-198

  Brunt, Tibor M ^a   Nagy, Constanze ^b   Bücheli, Alexander ^c   Martins, Daniel ^d   Ugarte, Miren ^e   Beduwe, Cécile ^f   Ventura Vilamala, Mireia ^g  

^a NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^b Suchthilfe Wien gGmbH   (Austria)

^c Safer Nightlife Switzerland   (Switzerland)

^d INSTITUTO PIAGET   (Portugal)

^e Ai Laket   (Spain)

^f Harm Reduction among drug users   (Belgium)

^g Energy Control Asociación Bienestar y Desarrollo   (Spain)

Author keywords

adulterants; amphetamine; cocaine; drug testing; ecstasy; new psychoactive substances; purity

Indexed keywords

COPYRIGHTS; DISTRIBUTED COMPUTER SYSTEMS; DRUG DOSAGE;

ADULTERANT; AMPHETAMINE; COCAINE; DRUG TESTING; ECSTASY; INFORMATION PROJECTS; NETHERLANDS; NEW PSYCHOACTIVE SUBSTANCE; PURITY; TESTING SYSTEMS;

COMMERCE;

(3 CHLOROPHENYL)PIPERAZINE; 4 FLUOROAMPHETAMINE; 4 FLUOROMETHAMPHETAMINE; 4 METHOXYAMPHETAMINE; 4 METHOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE; CAFFEINE; COCAINE; DEXTROMETHORPHAN; DILTIAZEM; HYDROXYZINE; LEVAMISOLE; LIDOCAINE; METHYLONE; MIDOMAFETAMINE; PHENACETIN; PROCAINE; PSYCHOTROPIC AGENT; TETRACAINE; UNCLASSIFIED DRUG; POWDER; STREET DRUG; TABLET;

ARTICLE; COLORIMETRY; DRUG INFORMATION; DRUG MARKETING; DRUG PURITY; DRUG SCREENING; EUROPE; GEOGRAPHIC DISTRIBUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; ADULT; DRUG CONTAMINATION; DRUG USE; HUMAN; MALE; POWDER; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS; TABLET;

ADULT; AMPHETAMINE; COCAINE; DRUG CONTAMINATION; DRUG USERS; EUROPE; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POWDERS; PSYCHOTROPIC DRUGS; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TABLETS;

EID: 84959378651     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1954     Document Type: Article

References (64)

1. H. J. Parker, J. Aldridge, F. Measham. Illegal Leisure: The Normalization of Adolescent Recreational Drug Use. Routledge, London 1998.
2. M. de Kort, T. Cramer. Pragmatism versus ideology: Dutch drug policy. J. Drug Issues. 1999, 29, 473.
3. A. Boys, J. Marsden, J. Strang. Understanding reasons for drug use amongst young people: a functional perspective. Health Educ. Res. 2000, 16, 457.
4. P. Tossmann, S. Boldt, M. D. Tensil. The use of drugs within the techno party scene in European metropolitan cities. Eur. Addict. Res. 2001, 7, 2.
5. G. K. Butler, A. M. Montgomery. Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use. Drug Alcohol Depend. 2004, 76, 55.
6. G. Dughiero, F. Schifano, G. Forza. Personality dimensions and psychopathological profiles of Ecstasy users. Hum. Psychopharm. 2001, 16, 635.
7. L. Orsolini, G. Francesconi, D. Papanti, A. Georgetti, F. Schifano. Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces. Hum. Psychopharm. 2015, 30, 302.
8. EMCDDA. European Drug Report 2015. EMCDDA, Lisbon, 2015.
9. Mixmag. Global Drug Survey 2014. Mixmag, London, 2014.
10. F. Goossens, T. Frijns, N. van Hasselt, M. van Laar. Het Grote Uitgaansonderzoek 2013. Utrecht, Trimbos Institute, 2014.
11. M. A. Bellis, K. Hughes, H. Lowey. Healthy nightclubs and recreational substance use. From a harm minimisation to a healthy settings approach. Addict. Behav. 2002, 27, 1025.
12. A. S. Christophersen. Amphetamine designer drugs – an overview and epidemiology. Toxicol. Lett. 2000, 112–113, 127.
13. I. P. Spruit. Monitoring synthetic drug markets, trends, and public health. Subst. Use Misuse. 2001, 36, 23.
14. A. C. Parrott. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl). 2004, 173, 234.
15. T. M. Brunt, M. W. Koeter, R. J. Niesink, W. van den Brink. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology (Berl). 2012, 220, 751.
16. I. P. Spruit. Ecstasy use and policy responses in the Netherlands. J. Drug Issues. 1999, 29, 653.
17. T. M. Brunt, R. J. Niesink. The Drug Information and Monitoring System (DIMS) in the Netherlands: implementation, results, and international comparison. Drug Test. Anal. 2011, 3, 621.
18. L. Keijsers, M. G. Bossong, A. J. Waarlo. Participatory evaluation of a Dutch warning campaign for substance-users. Health Risk Soc. 2007, 10, 283.
19. H. Kriener, R. Smid, G. Smekal. An inventory of on-site pill-testing interventions in the European Union. Vienna Social Projects. EMCDDA, Lisbon, 2001.
20. A. Benschop, M. Rabes, D.J. Korf. Pill Testing, Ecstasy & Prevention. Rozenberg, Amsterdam, 2002.
21. A. Bücheli, I. Quinteros-Hungerbühler, M. Schaub. Evaluation of Party Drug Prevention in the City of Zurich. Suchtmagazin. 2010, 5, 38.
22. J. Rovira, V. Ibáñez. Testeo y análisis de sustancias como práctica para una reducción de riesgos. Eguzkilore: Cuaderno del Instituto Vasco de Criminología. 2002, 16, 61.
23. D. Martins, H. Valente, C. Pires. Check!ng: the last frontier for Harm Reduction in party settings. Saúde e Sociedade. 2015, 24, 646.
24. I. Giraudon, P. Y. Bello. Monitoring ecstasy content in France: results from the National Surveillance System 1999-2004. Subst. Use Misuse. 2007, 42, 1567.
25. E. E. Tanner-Smith. Pharmacological content of tablets sold as "ecstasy": results from an online testing service. Drug Alcohol Depend. 2006, 83, 247.
26. T. M. Brunt, S. Rigter, J. Hoek, N. Vogels, P. van Dijk, R. J. Niesink. An analysis of cocaine powder in the Netherlands: content and health hazards due to adulterants. Addiction. 2009, 104, 798.
27. I. Evrard, S. Legleye, A. Cadet-Taïrou. Composition, purity and perceived quality of street cocaine in France. Int. J. Drug Policy. 2010, 21, 399.
28. N. Vogels, T. M. Brunt, S. Rigter, P. van Dijk, H. Vervaeke, R. J. M. Niesink. Content of ecstasy in the Netherlands: 1993-2008. Addiction. 2009, 104, 2057.
29. S. L. Kenyon, J. D. Ramsey, T. Lee, A. Johnston, D. W. Holt. Analysis for identification in amnesty bin samples from dance venues. Ther. Drug Monit. 2005, 27, 793.
30. A. M. Camilleri, D. Caldicott. Underground pill testing, down under. Forensic Sci. Int. 2005, 151, 53.
31. F. Caudevilla-Gálligo, J. Riba, M. Ventura, D. González, M. Farré, M. J. Barbanoj, J. C. Bouso. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. J. Psychopharm. 2012, 26, 1026.
32. T. M. Brunt, A. Poortman, R. J. Niesink, W. van den Brink. Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharm. 2011, 25, 1543.
33. O. Corazza, S. Assi, S. Malekianragheb, M. N. Beni, I. Bigdeli, Z. Aslanpour, F. Schifano. Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages. Int. J. Drug Policy. 2014, 25, 724.
34. N. Fucci, N. De Giovanni. Adulterants encountered in the illicit cocaine market. Forensic Sci. Int. 1998, 95, 247.
35. K. W. Simonsen, E. Kaa, E. Nielsen, D. Rollmann. Narcotics at street level in Denmark. A prospective investigation from 1995 to 2000. Forensic Sci. Int. 2003, (131), 162.
36. K. S. Kalasinsky, J. Hugel, S. J. Kish. Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J. Forensic Sci. 2004, 49, 1106.
37. M. M. van Deursen, E. R. Lock, A. J. Poortman-van der Meere. Organic impurity profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets seized in The Netherlands. Sci. Justice. 2006, 46, 135.
38. F. Bonadio, P. Margot, O. Delémont, P. Esseiva. Optimization of HS-SPME/GC-MS analysis and its use in the profiling of illicit ecstasy tablets (Part 1). Forensic Sci. Int. 2009, 187, 73.
39. A. Benschop, D.J. Korf. Bezoekers van de Jellinek testservice: Gebruikspatronen en beoordeling van de testservice in 2008 en 2011. Bonger Instituut voor Criminologie, Amsterdam, 2012.
40. I. Hungerbühler, A. Bücheli, M. Schaub. Drug Checking: A prevention measure for a heterogeneous group with high consumption frequency and polydrug use - evaluation of zurich's drug checking services. Harm Red. J. 2011, 8, 16.
41. D. Allemann, H. Pauli, A. Mürner, H.J. Helmlin, S. Steiner. Substance Testing on the Dance Floor with a Mobile High-tech Lab. Poster Club Health, Zürich, 2010.
42. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2014. United Nations, Vienna, 2014.
43. M. G. Bossong, J. P. van Dijk, R. J. Niesink. Methylone and mCPP, two new drugs of abuse? Addict. Biol. 2005, 10, 321.
44. M. Bossong, T. Brunt, J. P. van Dijk, S. Rigter, J. Hoek, H. Goldschmidt, R. J. Niesink. mCPP: an undesired addition to the ecstasy market. J. Psychopharm. 2010, 24, 1395.
45. F. Linsen, R. P. Koning, M. van Laar, R. J. Niesink, M. W. Koeter, T. M. Brunt. 4-Fluoroamphetamine in the Netherlands: more than a one-night stand. Addiction. 2015, 110, 1138.
46. United Nations Office on Drugs and Crime (UNODC). The Challenge of New Psychoative Substances. United Nations, Vienna, 2013.
47. J. van Amsterdam, D. Nutt, W. van den Brink. Generic legislation of new psychoactive drugs. J. Psychopharm. 2013, 27, 317.
48. S. D. Brandt, L. A. King, M. Evans-Brown. The new drug phenomenon. Drug Test. Anal. 2014, 6, 587.
49. European Commission. Drug precursors: EU summary report 2012. European Commission, Brussels, 2012.
50. United Nations Office on Drugs and Crime (UNODC). Global Synthetic Drugs assessment. United Nations, Vienna, 2014.
51. E. M. Gaertner, S. A. Switlyk. Dermatologic complications from levamisole-contaminated cocaine: a case report and review of the literature. Cutis. 2014, 93, 102.
52. T. T. Muirhead, M. J. Eide. Images in clinical medicine. Toxic effects of levamisole in a cocaine user. New Engl. J. Med. 2011, 364, e52.
53. T. Pearson, M. Bremmer, J. Cohen, M. Driscoll. Vasculopathy related to cocaine adulterated with levamisole: A review of the literature. Dermat. Online. 2012, 18, 1.
54. J. Graf, K. Lynch, C. L. Yeh, L. Tarter, N. Richman, T. Nguyen, A. Kral, S. Dominy, J. Imboden. Purpura, cutaneous necrosis, and antineutrophil cytoplasmic antibodies associated with levamisole-adulterated cocaine. Arthritis Rheuma. 2011, 63, 3998.
55. National Institute for Public Health and the Environment. Quick Scan Report levamisole. RIVM, Bilthoven, 2014.
56. P. Blanckaert, J. van Amsterdam, T. Brunt, J. van den Berg, F. van Durme, K. Maudens, J. van Bussel. 4-Methyl-amphetamine: a health threat for recreational amphetamine users. J. Psychopharm. 2013, 27, 817.
57. EMCDDA. New Psychoactive Substances in Europe. EMCDDA, Lisbon, 2015.
58. C. V. Gine, I. F. Espinosa, M. Ventura Vilamala. New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon? Drug Test. Anal. 2014, 6, 819.
59. L. Hondenbrink, J. J. Nugteren-van Lonkhuyzen, D. van der Gouwe, T. M. Brunt. Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre. Drug Alcohol Depend. 2015, 147, 109.
60. EMCDDA. EMCDDA–Europol Joint Report on a new psychoactive substance: 1-phenyl-2-(1-pyrrolidinyl)- 1-pentanone (α-PVP). EMCDDA, Lisbon, 2015.
61. EMCDDA. EMCDDA–Europol Joint Report on a new psychoactive substance: 4,4′-DMAR (4-methyl-5- (4-methylphenyl)-4,5-dihydrooxazol-2-amine). EMCDDA, Lisbon, 2014.
62. EMCDDA. Report on the risk assessment of 5-(2-aminopropyl)indole in the framework of the Council Decision on new psychoactive substances. EMCDDA, Lisbon, 2014.
63. BEWSD. September 2015 - Neurotoxic new substance found in ecstasy tablet. BEWSD, Brussels, 2015.
64. The Guardian. PMMA found in 'Superman' ecstasy possibly linked to four deaths. Press Association, The Guardian, London, January 2015.